What is Aurealis Pharma?
Aurealis Pharma operates at the intersection of regenerative medicine and oncology, focusing on the development of innovative cell and gene therapies. The company's core competency lies in its unique platform designed to treat chronic wounds, inflammatory diseases, and various forms of cancer. By addressing the underlying mechanisms of these complex pathologies, Aurealis Pharma aims to redefine patient outcomes in high-acuity medical segments such as diabetic foot ulcers. The company's strategic focus on multi-target therapies positions it as a high-potential player in the global biotechnology landscape, emphasizing both scientific rigor and commercial scalability.
How much funding has Aurealis Pharma raised?
Aurealis Pharma has raised a total of $10.8M across 3 funding rounds:
Angel/Seed
$1.8M
Angel/Seed
$3.3M
Series A
$5.8M
Angel/Seed (2014): $1.8M with participation from Tekes
Angel/Seed (2016): $3.3M led by Finnvera plc
Series A (2017): $5.8M supported by Finnvera plc and Tekes
Key Investors in Aurealis Pharma
Tekes
Tekes is a Finnish government agency that provides funding for research and development, specifically focusing on the commercialization of innovative ideas and the transition of academic research into viable commercial successes.
Finnvera plc
Finnvera is a specialized financing company owned by the State of Finland that acts as the official Export Credit Agency, providing loans, guarantees, and risk-sharing services to support the growth and internationalization of Finnish enterprises.
What's next for Aurealis Pharma?
With the recent influx of capital, Aurealis Pharma is expected to prioritize the advancement of its lead candidates through the regulatory pipeline. The strategic roadmap likely includes expanding clinical trial capacity and refining manufacturing processes to ensure the scalability of its gene therapy assets. As the company moves into this next phase of growth, stakeholders will be monitoring the progression of its pipeline and the potential for strategic partnerships with larger pharmaceutical entities. The focus remains on achieving key clinical milestones that will validate the efficacy of its platform and pave the way for future commercialization efforts in the global healthcare market.
See full Aurealis Pharma company page
